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STATEMENT OF TRANSLATIONAL RELEVANCE (120-150)
Although significant clinical benefit can be achieved with KIT inhibition in a subset of patients with melanoma driven by activating alterations in KIT, the development of secondary resistance is common. In this phase II study of nilotinib 400 mg BID, three of 11 patients with melanomas harboring KIT mutations or amplification who were refractory to a prior KIT inhibitor had disease control lasting 4 months or greater, with 2 achieving a partial response to therapy. One of 8 patients with melanomas metastatic to the brain harboring KIT mutations or amplification had disease control lasting 4 months or greater, with none achieving a radiographic response.
We conclude that nilotinib can achieve disease control in a subset of patients with melanoma harboring KIT alterations after progression on a prior tyrosine kinase inhibitor; however, the efficacy of this agent in KIT altered melanoma with brain metastasis is limited. The clinical activity of KIT inhibition in those melanomas driven by KIT alterations has been reported in patients treated with agents such as imatinib,(2-4) dasatinib,(5) sorafenib, (6) and sunitinib,(7) with efficacy observed in prospective trials of imatinib (8) (9) (10) and sunitinib. (11) Despite the clinical benefit achieved with KIT inhibition in select patients with melanoma harboring KIT mutations, most patients ultimately experience disease progression. Failure of these agents has been observed within the brain, (12) which may be related to the frequent development of brain metastases in patients with advanced melanoma, as well as the limited central nervous system (CNS) penetration of many small molecule kinase inhibitors.
Secondary resistance to KIT inhibition in patients with gastrointestinal stromal tumors (GIST), a disease characterized by activating deletions or insertions in KIT, is caused primarily by the development of secondary KIT mutations commonly affecting the tyrosine kinase domains. (13) There can additionally be outgrowth of resistant subclones present at baseline that are selected during KIT inhibitor therapy. In GIST, the use of alternative KIT tyrosine kinase inhibitors after progression on imatinib, including sunitinib, (14) sorafenib, (15) and regorafenib,(16) has proven beneficial; however, the efficacy of sequential KIT inhibitors in melanoma is unknown.
Nilotinib (Tasigna®, AMN107) is a tyrosine kinase inhibitor structurally derived from imatinib that is approved in the United States for the treatment of chronic and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia in patients resistant or intolerant to prior therapy with imatinib. Nilotinib binds to and inhibits the kinase domain of ABL/BCR-ABL and of the DDR, KIT, PDGF and several EPH receptor kinases with greater potency than imatinib, (17, 18) and maintains activity against a range of exon 9, 11 and 13 KIT mutations. (19) We conducted a phase II trial of nilotinib in patients with melanoma harboring KIT aberrations who experienced disease progression or intolerance to a prior KIT inhibitor.
Given the frequent complication of brain metastases in patients with this disease and the potential for second-generation inhibitors of KIT to have activity within the CNS, (20) 
MATERIALS AND METHODS

Study Design and Objectives
The primary objective was to assess the efficacy of nilotinib in patients with metastatic melanoma arising from acral, mucosal or chronically sun-damaged surfaces characterized by mutations or amplification of KIT after demonstration of disease progression or intolerance to a prior KIT tyrosine kinase inhibitor. Secondary objectives included efficacy assessment of nilotinib in patients with advanced KIT-mutant melanoma and CNS metastases. Tumor samples from all patients were prospectively tested for KIT mutation or amplification by quantitative polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH) as previously described. (8, 10) Patients who met eligibility criteria received nilotinib 400 mg by mouth twice daily. Safety evaluations, including clinical and laboratory assessments, were conducted at baseline, every week for four weeks, every two weeks for four weeks, every four weeks for 28 weeks, and then every three months subsequently. Adverse event severity was graded using the NCI Common Terminology Criteria for Adverse Events, v3.0. Tumor response was measured radiographically every eight weeks for 32 weeks and every 12 weeks subsequently using RECIST 1.0 criteria, and included brain imaging for those with CNS involvement. Patients remained on study until the time of progression or the development of unacceptable toxicity not manageable with dose modification.
Research. significant heart disease. All patients provided written-informed consent before initiating study procedures. The study was reviewed and approved by IRBs at all participating centers.
Trial Design
Cohort A employed an optimal Simon, two-stage design with 87% power to compare a null DCR of 5% with an alternative of 25%, with a one-sided type-I error of 7.5%. The target sample size was 28 patients, of whom 25 were expected to be evaluable for outcome. In the first stage, 13 evaluable patients would be assessed. If 2 or more patients achieved four-month disease control, an additional 12 evaluable patients would be assessed in the second stage. If 3 or more of 25 achieved four-month disease control, then nilotinib would be considered promising in this disease setting. A second feasibility cohort of 10 patients (Cohort B) was added after the study began to estimate the four-month DCR in patients with advanced, KIT-mutated melanoma and CNS metastases. Nilotinib would be of interest in this cohort if at least 2 of 10 patients achieved four-month disease control.
Statistical Methods
Baseline patient characteristics and adverse events were summarized using descriptive methods.
Adverse events were reported as the most severe manifestation of each event category during any cycle of treatment. Four-month disease control rate (DCR) was defined as the proportion of DCR and BORR. Time-to-progression (TTP) was defined as the time from initiation of nilotinib to the date of progression or last follow-up. Overall survival (OS) was defined as the time from initiation of nilotinib to the date of death or last follow-up. Four-month DCR and best overall response rates (BORR) are presented with 90% exact binomial confidence intervals. TTP and OS are presented using the method of Kaplan-Meier, with point-wise 90% confidence intervals estimated using log(-log(survival)) methodology.
Role of the Funding Source
Dr. Hodi developed the original study design and was responsible for the IND. Novartis provided investigational drug in addition to funding, and was involved in study design which was developed in conjunction with the authors. The study sponsor had no role in the data collection, the data analysis, data interpretation, writing of the report, or the decision to submit for publication.
Research. Table 1 . Patients were predominantly female (74%), with a median age of 67 years (range, 38 -85 years). Twelve (63%) patients had mucosal melanoma, four (21%) had acral melanoma, and three (16%) had melanoma arising from chronically sun-damaged skin (CSD). All patients had locoregionally advanced (5%) or distant disease (95%); most patients received one or more prior therapies.
Sixteen patients received prior imatinib, one received both sorafenib and imatinib (patient 2), and three received prior ipilimumab therapy. All patients previously treated with a KIT inhibitor experienced progression on those agents and were not enrolled onto this study due to intolerance of prior therapy. Six of the 8 patients treated on Cohort B received prior therapy with imatinib, and 2 patients were naïve to KIT inhibition. Patient demographic and disease characteristics were similar between Cohorts A and B.
Research. Tumor from the 19 treated patients was tested for the presence of KIT mutations, with 17 harboring such alterations (Tables 2 and 3 ). The specific mutations identified included exon 11 L576P (n = 4), exon 11 V560D (n = 1), exon 11 V560E (n = 1), exon 11 W557R (n = 1), exon 11 V559C (n = 1), exon 11 WKVVE 557-561 (n = 1), exon 13 K642E (n = 3), exon 13 Y646D (n = 1), exon 17 D820Y (n = 1), exon 17 N822K (n = 1), and exon 18 L831P (n = 1). One patient had tumor harboring two exon 13 mutations (R634Q and K642E). KIT amplification was tested in 12 cases, with 8 found to harbor such alteration. Two cases harbored amplification without a concurrent KIT mutation.
At the time of data analysis, 18 of the 19 treated patients were off-study, 14 of whom due to progressive disease. Median follow-up was 16.2 months in Cohort A (90% CI, 6.9 -37.5 months) and 11.7 months in Cohort B (90% CI, 2.1 months -∞).
Toxicity
Adverse events classified as possibly, probably or definitely related to nilotinib are shown in Supplemental Table 1 . Events that were recorded multiple times for any patient are reported only once according to the worst grade. Although nilotinib was generally well-tolerated, 17 of the 19 patients treated reported adverse events, with fatigue (26%) and low-grade musculoskeletal and gastrointestinal discomfort (32%) most commonly observed. Grade-3 toxicities were observed in 4 patients, and included rash (n = 1), elevated pancreatic enzymes (n = 2), and transaminitis and hyponatremia (n = 1). Grade 3 toxicity was managed by dose reduction to 400 mg QD (n = 2) or
Research. CI, 0.9 -5.5 months) and 2.6 months (90% CI, 1.8 -3.9 months; Figure 3A ) in Cohorts A and B, respectively.
Overall Survival. Eleven patients (57.9%) were deceased at the time of data analysis, with one patient lost to follow-up. The median OS in Cohort A was 14.2 months (90% CI, 7.1 months -∞) and was longer than observed in Cohort B (4.3 months; 90% CI, 3.5 -11.9 months; p = 0.05; Figure 3B ).
DISCUSSION
These results demonstrate that a subset of patients with melanomas harboring genetic alterations of KIT may benefit from nilotinib after experiencing disease progression to a prior KIT inhibitor.
Three of 11 patients without brain metastasis achieved disease control at four months with nilotinib, with observed progression-free survival times of 5.5, 11.5, and 37.5+ months. Notably, patients 3 and 20 achieved a durable PR and CR, respectively, to imatinib lasting 12.4 and 20 months, respectively, before achieving durable PRs to nilotinib, demonstrating that nilotinib can overcome the development of secondary resistance to imatinib. Based on the original study design for Cohort A which required three or more patients to achieve disease control at four months, the primary endpoint of four-month DCR was achieved. 
outcomes when compared with best-supportive care in the third-line setting. (25, 26) Importantly, mechanisms of secondary resistance in GIST, which commonly involve the development of secondary KIT mutations affecting the tyrosine kinase domains in exons 13 and 17, (27) (28) (29) appear to differ from those observed in melanoma driven by KIT alterations. Thus far, no such secondary mutations have been observed in KIT melanoma. Rather, the limited data available suggests that, in melanoma, the development of secondary NRAS mutations(11) and activation of the mTOR pathway by alternative mechanisms may result in secondary resistance. (30) In conclusion, the use of nilotinib in a subset of patients with melanoma harboring KIT alterations previously treated with an inhibitor of KIT can result in clinical benefit, although efficacy of this agent in brain metastasis is limited. Although this trial is underpowered to conclude clinical benefit, the data suggest further studies of sequential KIT inhibitor therapy for this molecular subset of patients is warranted.
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